von Tobias Borgers | Feb 14, 2024 | Boehringer
Boehringer Ingelheim is developing a biologicals development centre (BDC) at its facility in Biberach, Germany. Credit: Boehringer Ingelheim. A ground-breaking ceremony for the BDC was held in June 2018. Credit: Boehringer Ingelheim. BDC was inaugurated in April 2023....
von Tobias Borgers | Feb 14, 2024 | Boehringer
Weltweit führendes Unternehmen der Tiermedizin führt Veeva Vault Clinical und Veeva Vault RIM für mehr Effizienz, Transparenz und Geschwindigkeit ein BARCELONA, Spanien, 14. Februar 2024 /PRNewswire/ — Veeva Systems (NYSE: VEEV) gab heute bekannt, dass...
von Tobias Borgers | Feb 14, 2024 | Fachzeitschriften
Effizienz durch Engineering in den Anfangsphasen Die biotechnologische Produktion vom Labor auf industriellen Maßstab zu bringen, ist eine anspruchsvolle Aufgabe. Es erfordert tiefgreifende Erfahrung und umfassendes Know-how, um einen profitablen Business Case zu...
von Tobias Borgers | Feb 2, 2024 | Glaxo
When Matt Hill, PhD, was in graduate school, the human genome sequence was more or less finished and companies like 454 and Solexa were starting to make waves in next-gen sequencing (NGS). But Hill became more enamored with synthetic biology—engineering the genetic...
von Tobias Borgers | Feb 2, 2024 | Glaxo
Omjjara is the first medicine in the EU specifically indicated for treating splenomegaly (enlarged spleen) or symptoms in adult myelofibrosis patients with moderate to severe anaemia Authorisation may address high unmet need, with nearly all myelofibrosis patients...
